Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer
نویسندگان
چکیده
منابع مشابه
Afatinib (BIBW‐2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non‐small‐cell lung cancer
Lung cancer is the leading cause of cancer death in the USA. Approximately 215,020 new cases (114,690 men and 100,330 women) were diag‐ nosed and 161,840 died of lung cancer in 2008 (National Cancer Institute [NCI] 2009). The extremely high lung cancer‐related mortality, demonstrates the limited efficacy of traditional cytotoxic chemotherapy in patients with this disease [1,2]. In the past few ...
متن کاملA novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells.
Lung cancer is the leading cause of cancer-related mortality in the world, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases. Since more than 60% of NSCLC cases express the epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors are used to treat NSCLC. However, due to the acquired resistance associated with EGFR-targeted therapy, other strategi...
متن کاملAfatinib treatment in advanced non-small cell lung cancer.
Despite some recent advances in the management of advanced non-small cell lung cancer (NSCLC), prognosis for these patients remains poor. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have however provided a new therapeutic option in this disease setting and EGFR mutation testing is now routine practice for newly diagnosed NSCLC patients. A proportion ...
متن کاملTarget binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.
Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized as an oncogenic driver in epithelial cancers. Several targeted drugs have been developed, including antibodies and small-molecule kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions. Understanding the precise pharmacologica...
متن کاملTitle : Target Binding Properties and Cellular Activity of Afatinib ( BIBW 2992 ) , an Irreversible
Deregulation of the ErbB receptor network is well recognized as an oncogenic driver in epithelial cancers. Several targeted drugs have been developed, including antibodies and small molecule kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions. Understanding the precise pharmacological properties of these compounds is important for optimal use in clin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapy
سال: 2011
ISSN: 1475-0708,1744-831X
DOI: 10.2217/thy.10.86